Onconova Therapeutics, Inc. — Q2 2022 Form 10-Q
Filing identity: The provided filing is for Onconova Therapeutics, Inc. (Nasdaq: ONTX), not Traws Pharma, Inc. The mismatch should be verified before relying on this summary. Reporting period ended June 30, 2022; filed August 15, 2022. Financial statements are unaudited.
Business context
Onconova is a clinical-stage biopharmaceutical company developing oncology candidates. Its two clinical-stage programs are narazaciclib, a multi-targeted kinase inhibitor, and rigosertib, being studied alone or in combination. Revenue is limited to recognition of deferred upfront payments under its SymBio collaboration.
Financial performance and liquidity
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Revenue | $57,000 | $113,000 |
| Operating expenses | $4.177 million | $8.365 million |
| Operating loss | $4.120 million | $8.252 million |
| Net loss | $4.024 million | $8.146 million |
| Basic and diluted loss per share | $0.19 | $0.39 |
| Net cash used in operating activities | Not presented for the quarter | $8.510 million |
Revenue is immaterial relative to operating costs; the filing does not present a meaningful gross margin. At June 30, cash and cash equivalents were $46.533 million, working capital was $41.6 million, total assets were $48.074 million, and total liabilities were $9.590 million. No debt balance is reported in the supplied financial statements. Cash declined $8.537 million from year-end 2021. Accumulated deficit was $452.865 million.
Changes versus prior comparable periods
- Q2 revenue was unchanged from 2021 at $57,000. Six-month revenue was unchanged at $113,000.
- Q2 net loss narrowed to $4.024 million from $4.231 million; six-month net loss narrowed to $8.146 million from $8.946 million. Lower general and administrative costs and higher other income contributed; Q2 2021 also included a $427,000 warrant fair-value gain.
- Operating expenses fell by $525,000 in Q2 and $491,000 in the first half. General and administrative expense declined, mainly due to lower 2021 investor-relations, proxy-solicitation and special-meeting costs. R&D expense rose 10% in Q2 and 7% for the first half, including higher personnel, stock compensation and manufacturing costs.
- First-half operating cash use improved from $10.955 million in 2021 to $8.510 million in 2022. Unlike 2021, there were no financing cash proceeds in the 2022 half-year period; 2021 included $35.651 million of financing inflows.
Outlook, commentary and risks
- Management expects continuing operating losses and says additional financing will be needed to develop candidates and fund operations. The company may delay, scale back or eliminate activities if funding is not obtained; financing could be dilutive or require concessions in collaborations or licensing.
- The filing gives two runway statements: the liquidity note says cash will fund operations and ongoing trials for more than 12 months from filing, while MD&A says at least 18 months. Management also expects 2022 net cash expenditures to be slightly higher than 2021, with clinical-trial, staffing and possible in-licensing costs potentially increasing.
- Narazaciclib US Phase 1 dose escalation had completed the fourth cohort with no dose-limiting toxicities reported; the fifth cohort was ongoing. The partner-led China study was enrolling at its fifth cohort. Clinical benefit and the recommended Phase 2 dose remain unestablished.
- Rigosertib plus a PD-1 inhibitor continued enrolling in a Phase 1/2a study in KRAS-mutated NSCLC; final Phase 1 results were expected in late 2022. Preliminary results cited by the company were small and early, including clinical benefit in 3 of 7 evaluable patients.
- A rigosertib monotherapy study in rare RDEB-associated squamous cell carcinoma remained ongoing. The filing describes a complete remission in one patient, but emphasizes that available safety and efficacy evidence was from only one patient.
- The company reported no material COVID-19 impact through June 30, 2022, but noted future effects on manufacturing, trials and R&D were uncertain. It reported no pending material legal proceedings and stated disclosure controls were effective.
Key facts for investors to verify
- Confirm the filing belongs to the intended company: the request names Traws Pharma, but the filing identifies Onconova Therapeutics.
- Reconcile the stated cash runway of “more than 12 months” versus “at least 18 months,” and assess funding needs against ongoing cash burn.
- Check subsequent clinical-trial updates, especially narazaciclib dose escalation and the small early rigosertib datasets.
- Review the company’s financing capacity and potential dilution, including remaining availability under its at-the-market equity program.